Hepatitis: Casabona J

Almeda J, Casabona J, Allepuz A, García-Alcaide F, del Romero J, Tural C, Colm J, Bolao F, Campins M, Domínguez A, Force L, Giménez A, Guerra-Romero L, Anonymous00243. · Centre de Estudis Espidemiològics sobre la Sida a Catalunya. Hospital Universitari Germans Trias i Pujol. Badalona. España. · Enferm Infecc Microbiol Clin. · Pubmed #12372236 links to  free full text

Abstract: Evidence is lacking on the possible efficacy and effectiveness of non-occupational postexposure prophylaxis (PEP). However, because of its biological plausibility, the use of antiretroviral (ARV) drugs to prevent the development of infection in certain cases of accidental or sporadic exposure has begun to be considered as common clinical practice. Previous studies performed in Spain have demonstrated both the demand and the prescription of ARV as PEP and especially the diversity and inconsistency in the criteria used. In this context, in April of 2000 the Centre for Epidemiological Studies on AIDS of Catalonia (CEESCAT) (Department of Health and Social Security of the Autonomous Government of Catalonia), in collaboration with the National AIDS Plan and the AIDS Study Group (GESIDA), promoted the creation of a working group for the drafting of recommendations for PEP against HIV outside the occupational health context. The recommendations have been made bearing in mind the exceptional character of the exposure, the time elapsed since exposure, as well as evaluation of the risk of infection according to the type of exposure and the information available on the source of infection. In addition, the recommendations include the immediate measures necessary, as well as the preventive measures and clinical follow-up required both for HIV and for other infectious agents. All PEP regimens should be started within 72 hours of exposure and appropriate daily doses of two nucleoside reverse transcriptase inhibitors (NRTIs) and a protease inhibitor (PI), or two NRTIs and a non-nucleoside reverse transcriptase inhibitor (NNRTIs), should be administered for four weeks, bearing in mind the pharmacological and clinical situation of the source person. These recommendations should be updated periodically.

Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J, Anonymous00385. · Centre d'Estudis Epidemiològics sobre ITS/VIH/SIDA de Catalunya, Badolona, Spain (CEEISCAT, coordinating center). · J Acquir Immune Defic Syndr. · Pubmed #18297762 No free full text.

Abstract: OBJECTIVE: We analyze the factors related to progression to AIDS or death in HIV-infected patients from the Proyecto para la Informatización del Seguimiento Clínico epidemiológico de los pacientes con Infección por VIH/SIDA (PISCIS) Cohort and we assess the optimal time to initiate highly active antiretroviral therapy (HAART) taking lead time into account. METHODS: We selected naive patients who were AIDS-free and initiated HAART after January 1998. Statistical analyses were performed using Cox proportional hazards models. Lead time was defined as the time it took the deferred group with an early disease stage to reach the later stage. The analysis accounting for lead time was performed using multiple imputation methods based on estimates from the pre-HAART period as described elsewhere. RESULTS: Multivariate analysis on 2035 patients (median follow-up = 34.3 months) showed significantly higher hazard ratios (HRs) for a CD4 count <200 cells/microL (HR = 3.79, 95% confidence interval [CI]: 2.18 to 6.57), HIV-1 RNA level >100,000 copies/mL (HR = 1.84, 95% CI: 1.26 to 2.69), and hepatitis C virus (HCV) coinfection (HR = 2.40, 95% CI: 1.65 to 3.49), whereas a lower risk was found for those who started HAART between January 2001 and June 2004 (HR = 0.55, 95% CI: 0.30 to 0.90). When lead time and unseen events were included, we found a higher risk of progression to AIDS among patients who deferred treatment when the CD4 count reached <200 cells/microL (HR = 2.97, 95% CI: 1.91 to 4.63) and 200 to 350 cells/microL (HR = 1.85, 95% CI: 1.03 to 3.33) compared with those who started treatment with CD4 counts from 200 to 350 cells/microL and >350 cells/microL, respectively. CONCLUSIONS: Advanced HIV disease, HCV coinfection, and early HAART period were determinants of AIDS progression or death. Lead-time analysis in asymptomatic HIV-infected patients suggests that the best time to start HAART is before the CD4 count falls to lower than 350 cells/microL.

González V, Martró E, Folch C, Esteve A, Matas L, Montoliu A, Grífols JR, Bolao F, Tural C, Muga R, Parry JV, Ausina V, Casabona J. · Microbiology Service, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. · Eur J Clin Microbiol Infect Dis. · Pubmed #18027006 No free full text.

Abstract: Within the framework of hepatitis C virus (HCV) prevalence monitoring, we evaluated oral fluid (OF), which is richer in IgG than whole saliva, as a possible alternative to serum for the detection of HCV antibodies. Paired OF and serum samples were collected from 90 individuals, including 45 HCV-positives and 45 HCV-negatives. The detection of HCV antibodies in both serum and OF was performed using the Ortho HCV 3.0 SAVe enzyme-linked immunosorbent assay (ELISA) (Ortho-Clinical Diagnostics, Inc., Raritan, NJ), but a modified, more sensitive protocol was used to process OF. The sensitivity and specificity of this assay were 86.67% (95% confidence interval (CI): 72.51-94.46%) and 100% (95% CI: 90.20-99.80%) in OF and 100% in serum. The correlation obtained between both types of clinical specimens was excellent (k: 0.87, 95% CI: 0.66-1.07). However, the negative predictive value (NPV) of the assay in OF decreased with the prevalence of HCV infection in the population studied. Our results suggest that the modified Ortho HCV 3.0 SAVe ELISA is suitable for the detection of HCV antibodies in OF for epidemiological studies. Using this assay, we observed an unadjusted anti-HCV prevalence of 78.6% among a population of intravenous drug users; when adjusted to account for assay sensitivity, this prevalence may be closer to 90%.

Folch C, Meroño M, Casabona J. · Centro de Estudios Epidemiológicos sobre el HIV/Sida de Cataluña (CEESCAT). Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. · Med Clin (Barc). · Pubmed #17145000 No free full text.

Abstract: BACKGROUND AND OBJECTIVE: To estimate the prevalence of risk behaviors related to drug use and to identify factors associated with of accepting and passing on used syringes among intravenous drug users (IDU) recruited in Barcelona city and other surrounding areas in 2004. SUBJECTS AND METHOD: A cross-sectional study of IDU recruited from the streets by ex-IDU interviewers. A standardized and anonymous questionnaire which explored behaviors in the previous 6 months was used. Saliva samples were collected to determine human immunodeficiency virus (HIV) prevalence. Logistic regression models were used to identify determinants of accepting and passing on used syringes. RESULTS: Of the 300 participants, 17.7% and 13.3% accepted and passed on used syringes, respectively. 74.8% practiced front-backloading (to prepare the drug solution in a syringe and then divide it up into other syringes) and 77.9% shared other equipment. The prevalence of HIV was 57.7%. The predictors of accepting used syringes were using more than 4 drugs (odds ratio [OR] = 5.6), having a positive hepatitis C virus status (OR = 7.3), practising front/backloading (OR = 12.6) and having an IDU steady partner (OR = 2.9); and with passing on used syringes were practicing front/backloading (OR = 4.9), having an IDU steady partner (OR = 5.8), and having sexual risk behaviors with casual partners (OR = 4.0). Starting to inject drugs older than 15 years of age was a protective factor (OR = 0.2). CONCLUSIONS: The prevalence of risk behaviors related to drug use remains high, especially indirect sharing, just as the prevalence of HIV and hepatitis C virus. Prevention programs should be targeted to IDU, especially to young IDU, polydrug users and those who have an IDU steady partner.